BioDelivery Sciences International

BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. Our development strategy focuses on utilization of the Food and Drug Administration's (FDA's) 505(b)(2) approval process. This regulatory pathway allows us to potentially obtain more timely and efficient approval of new formulations of previously approved therapeutics. Our particular area of focus is the development and commercialization of products in the areas of pain management and addiction medicine. These are areas where we believe our drug delivery technologies and products can best be applied to address critical unmet medical needs. Our marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. We look to improve upon existing drugs by enhancing their efficacy and/or ease of administration, or create new therapies, all with the ultimate goal of enhancing patient care.
Company Growth (employees)
Type
Public
HQ
Raleigh, US
Founded
1997
Size (employees)
40 (est)
Website
bdsi.com
BioDelivery Sciences International was founded in 1997 and is headquartered in Raleigh, US

Key People at BioDelivery Sciences International

Frank E. O'Donnell, Jr.

Frank E. O'Donnell, Jr.

Executive Chairman
Mark A. Sirgo

Mark A. Sirgo

Senior Vice President of Commercialization and Corporate Development
Albert J. Medwar

Albert J. Medwar

Vice President, Marketing and Corporate Development
William B. Stone

William B. Stone

Lead Director

BioDelivery Sciences International Office Locations

BioDelivery Sciences International has an office in Raleigh
Raleigh, US (HQ)
225 4131 Parklake Ave

BioDelivery Sciences International Metrics

BioDelivery Sciences International Financial Metrics

Revenue (2016)

$15.5 m

Revenue growth (2015-16), %

(68%)

Gross profit

$4.3 m

Gross profit margin (2016), %

28%

Net income (2016)

($67.1 m)

Market capitalization (21-Mar-2017)

$102.8 m

Closing share price (21-Mar-2017)

$1.9

Cash (31-Dec-2016)

$32 m
BioDelivery Sciences International's current market capitalization is $102.8 m.
BioDelivery Sciences International's revenue was reported to be $15.5 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$11.4 m$38.9 m$48.2 m$15.5 m

Revenue growth, %

243%24%(68%)

Cost of goods sold

$4.9 m$8.1 m$11.3 m

Gross profit

$9.3 m$34 m$40.1 m$4.3 m

Gross profit Margin, %

82%87%83%28%

Operating expense total

$65.7 m$72.7 m$75.3 m$68.2 m

EBIT

($56.4 m)($38.7 m)($35.2 m)($63.9 m)

EBIT margin, %

(497%)(99%)(73%)(411%)

Interest expense

$2.5 m$3.3 m

Pre tax profit

($57.4 m)($54.2 m)

Income tax expense

($129 k)

Net Income

($57.4 m)($54.2 m)($37.7 m)($67.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$23.2 m$70.5 m$83.6 m$32 m

Accounts Receivable

$2.8 m$3.1 m$2.5 m$3.6 m

Inventories

$630.7 k$2.9 m$3.9 m$4.1 m

Current Assets

$26.6 m$78.3 m$92.5 m$43.1 m

PP&E

$3.9 m$4.3 m$4.2 m

Goodwill

$2.7 m$2.7 m$2.7 m$2.7 m

Total Assets

$38 m$89.3 m$102.8 m$52.3 m

Accounts Payable

Current Liabilities

$25 m$29.2 m$28.1 m$19.9 m

Additional Paid-in Capital

$150.5 m$259.9 m$274.9 m$292.7 m

Retained Earnings

($151.3 m)($205.5 m)($243.2 m)($310.3 m)

Total Equity

$54.4 m$31.7 m

Financial Leverage

1.6 x3.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($57.4 m)($54.2 m)($37.7 m)($67.1 m)

Depreciation and Amortization

$1.3 m$1.1 m$1.3 m$1.4 m

Accounts Receivable

($2.3 m)($347 k)$653 k($1.1 m)

Inventories

($1.8 m)($730 k)($810 k)

Accounts Payable

($656.8 k)$4.3 m$5.1 m($1.3 m)

Cash From Operating Activities

($60.1 m)($28.8 m)($3.7 m)($54 m)

Purchases of PP&E

($76.9 k)($1.6 m)($701 k)($405 k)

Cash From Investing Activities

($76.9 k)($1.6 m)($701 k)($405 k)

Cash From Financing Activities

$20.2 m$77.7 m$17.5 m$2.8 m

Interest Paid

$742.1 k$1.4 m$1.9 m$2.9 m

Income Taxes Paid

$80.5 k$80 k$80 k

BioDelivery Sciences International Market Value History

BioDelivery Sciences International Online Presence

BioDelivery Sciences International Company Life

You may also be interested in